title: Efficacy of cyclosporin with corticotropin for refractory ulcerative colitis.
abstract: OBJECTIVE
  Cyclosporin was reported to be useful for steroid-resistant severe ulcerative colitis in the short term, but limited data are available on the long-term follow-up of such patients. Our aim was to assess the short- and long-term efficacy of combination therapy with cyclosporin and corticotropin for steroid-resistant ulcerative colitis.
  
  
  METHODS
  Twenty-one patients with ulcerative colitis who did not respond to corticosteroid therapy, were treated with corticotropin, and 9 patients (43%) of them achieved complete remission. Twelve patients (57%) who did not achieve complete remission by corticotropin alone were given combination therapy with cyclosporin and corticotropin.
  
  
  RESULTS
  In 12 patients who received combined therapy with cyclosporin and corticotropin, clinical severity was distinctly improved in 11 patients (92%) by combination therapy within 2 weeks and 7 patients (58.3%) entered into complete remission with salicylazosulfapyridine or 5-aminosalicylic acid alone. Two patients (16.7%) demonstrated insufficient effect and continue to receive a lower dosage of cyclosporin or corticosteroid. Three patients (25%) failed to respond to the combination therapy and required colectomy. Three of 7 patients who entered into remission relapsed 0.5, 5 and 5.5 months (average: 3.7 months) after cyclosporin withdrawal, but the clinical severity at the time of relapse was milder than that at the beginning of the treatment, namely, moderate in 2 patients, and mild in 1 patient. There were no significant adverse effects in our series.
  
  
  CONCLUSIONS
  We demonstrated that oral cyclosporin in combination with corticotropin was highly effective for ulcerative colitis refractory to corticosteroid or corticotropin therapy and severe relapse was uncommon during several years of follow-up.
authors.affiliation: Division of Gastroenterology, Department of Internal Medicine Toyohashi, Municipal Hospital, Aotake-cho, Toyohashi, Aichi, 441-8570, Japan. s_okamura415@yahoo.co.jp
authors.forename: Shozo
authors.initials: S
authors.lastname: Okamura
authors.forename: Hiizu
authors.initials: H
authors.lastname: Aoki
authors.forename: Shinji
authors.initials: S
authors.lastname: Ohashi
authors.forename: Fumihiro
authors.initials: F
authors.lastname: Urano
authors.forename: Masaya
authors.initials: M
authors.lastname: Shimodaira
authors.forename: Shinichi
authors.initials: S
authors.lastname: Kanamori
authors.forename: Hideki
authors.initials: H
authors.lastname: Ishikawa
authors.forename: Kose
authors.initials: K
authors.lastname: Segawa
mesh_terms: D000293:Adolescent; D000324:Adrenocorticotropic Hormone / Q000008:administration & dosage* / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D016572:Cyclosporine / Q000008:administration & dosage* / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D000324:Adrenocorticotropic Hormone